"saxagliptin" meaning in English

See saxagliptin in All languages combined, or Wiktionary

Noun

IPA: /ˌsæk.səˈɡlɪp.tɪn/ [General-American]
Etymology: From [Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”). Etymology templates: {{af|en||-gliptin|t2=dipeptidyl aminopeptidase-IV inhibitor}} [Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”) Head templates: {{en-noun|-}} saxagliptin (uncountable)
  1. (pharmacology) A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze. Wikipedia link: saxagliptin Tags: uncountable Categories (topical): Pharmaceutical drugs
{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-gliptin",
        "t2": "dipeptidyl aminopeptidase-IV inhibitor"
      },
      "expansion": "[Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "saxagliptin (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "English terms suffixed with -gliptin",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "glosses": [
        "A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze."
      ],
      "id": "en-saxagliptin-en-noun-mVY64GxO",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "hypoglycemic",
          "hypoglycemic"
        ],
        [
          "drug",
          "drug"
        ],
        [
          "orally",
          "orally"
        ],
        [
          "hydrate",
          "hydrate"
        ],
        [
          "degradation",
          "degradation"
        ],
        [
          "incretin",
          "incretin"
        ],
        [
          "insulin",
          "insulin"
        ],
        [
          "pancreas",
          "pancreas"
        ],
        [
          "Onglyza",
          "Onglyza"
        ],
        [
          "metformin",
          "metformin"
        ],
        [
          "Kombiglyze",
          "Kombiglyze"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "saxagliptin"
      ]
    }
  ],
  "sounds": [
    {
      "ipa": "/ˌsæk.səˈɡlɪp.tɪn/",
      "tags": [
        "General-American"
      ]
    }
  ],
  "word": "saxagliptin"
}
{
  "etymology_templates": [
    {
      "args": {
        "1": "en",
        "2": "",
        "3": "-gliptin",
        "t2": "dipeptidyl aminopeptidase-IV inhibitor"
      },
      "expansion": "[Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”)",
      "name": "af"
    }
  ],
  "etymology_text": "From [Term?] + -gliptin (“dipeptidyl aminopeptidase-IV inhibitor”).",
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "saxagliptin (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English term requests",
        "English terms suffixed with -gliptin",
        "English uncountable nouns",
        "Pages with 1 entry",
        "en:Pharmaceutical drugs"
      ],
      "glosses": [
        "A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "hypoglycemic",
          "hypoglycemic"
        ],
        [
          "drug",
          "drug"
        ],
        [
          "orally",
          "orally"
        ],
        [
          "hydrate",
          "hydrate"
        ],
        [
          "degradation",
          "degradation"
        ],
        [
          "incretin",
          "incretin"
        ],
        [
          "insulin",
          "insulin"
        ],
        [
          "pancreas",
          "pancreas"
        ],
        [
          "Onglyza",
          "Onglyza"
        ],
        [
          "metformin",
          "metformin"
        ],
        [
          "Kombiglyze",
          "Kombiglyze"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A hypoglycemic drug taken orally in the form of its hydrate C₁₈H₂₅N₃O₂·H₂O in the treatment of type 2 diabetes. It acts by inhibiting the degradation of incretins, which results in increased secretion of insulin by the pancreas. It is marketed under the trademark Onglyza and when used in combination with metformin, under the trademark Kombiglyze."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ],
      "wikipedia": [
        "saxagliptin"
      ]
    }
  ],
  "sounds": [
    {
      "ipa": "/ˌsæk.səˈɡlɪp.tɪn/",
      "tags": [
        "General-American"
      ]
    }
  ],
  "word": "saxagliptin"
}

Download raw JSONL data for saxagliptin meaning in English (2.0kB)


This page is a part of the kaikki.org machine-readable English dictionary. This dictionary is based on structured data extracted on 2024-09-22 from the enwiktionary dump dated 2024-09-20 using wiktextract (af5c55c and 66545a6). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.

If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.